{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:06Z","timestamp":1790794986428,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite substantial therapeutic advances, multiple myeloma (MM) continues to be an important contributor to cancer-related mortality in the United States. Understanding long-term mortality patterns is essential for guiding equitable clinical and public health strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used CDC WONDER mortality data from 1999\u20132023 to evaluate MM-related deaths among U.S. adults aged \u226525 years. Age-adjusted mortality rates (AAMRs) were calculated using direct standardization to the 2000 U.S. population. Temporal trends were examined using Joinpoint regression to estimate annual percent changes (APCs) and identify significant shifts over time. Analyses were stratified by age, sex, race\/ethnicity, state, and urbanization level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nationally, MM mortality declined over the study period. Most age groups younger than 85 years showed statistically significant decreases in AAMR, whereas adults aged \u226585 years experienced a modest increase (APC = +0.67; 95% CI, 0.48\u20130.86). Males consistently exhibited higher AAMRs than females, although both showed declining trends. Substantial and persistent disparities were observed across racial and ethnic groups, as well as geographic and urbanization categories. Notable state-level heterogeneity was evident, with some states\u2014including New York, Ohio, and Kansas\u2014showing accelerated recent declines in mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From 1999 to 2023, MM-related mortality in the U.S. declined overall, but substantial and persistent disparities remained by age (notably a rising burden among the oldest adults), race\/ethnicity, sex, geography, and urbanization. These findings underscore the need for targeted research that links diagnosis, treatment uptake, and outcomes, and for policies to ensure equitable access to proven MM therapies so that survival gains are distributed more uniformly across all population groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1735565","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:22Z","timestamp":1765521262000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Trends in mortality rates associated with multiple myeloma in the United States, 1999\u20132023"],"prefix":"10.3389","volume":"15","author":[{"given":"Ye","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124799","article-title":"Trends in early mortality from multiple myeloma (MM): A population-based analysis","volume":"134","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24","article-title":"MM-761 multiple myeloma mortality trends before pandemic, stratified by year sex, and race: 1999-2019","volume":"24","author":"Faisal Aslam","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00001","article-title":"Clinical applications and future directions of minimal residual disease testing in multiple myeloma","volume":"10","author":"Oliva","year":"2020","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e24039","article-title":"Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database","volume":"42","author":"Faisal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210375","article-title":"Trends in multiple myeloma incidence and mortality (1991-2021) in the United States: A comprehensive analysis of gender and state-level disparities","volume":"144","author":"Bhanushali","year":"2024","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25","article-title":"MM-737: temporal trends and racial disparities in multiple myeloma mortality across the United States\u2014A CDC WONDER analysis","volume":"25","author":"Khan","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25","article-title":"MM-1279: chronic kidney disease and multiple myeloma: trends and inequities in US mortality (1999\u20132023)","volume":"25","author":"Hussain","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003834","article-title":"MM-208: trends in multiple myeloma and cardiovascular disease-related mortality (1999\u20132023): analysis of the CDC WONDER database","volume":"25","author":"Faheem","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206738","article-title":"Trends in mortality due to hematologic Malignancies among patients aged 25 and older in the United States: annual trends and insights on gender disparities from the CDC wonder database","volume":"144","author":"Durugu","year":"2024","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"14564","DOI":"10.1038\/s41598-024-65590-4","article-title":"Multiple myeloma incidence and mortality trends in the United States, 1999-2020","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10322","article-title":"Disparities in multiple myeloma mortality rate trends by demographic status in the USA","volume":"4","author":"Doddi","year":"2024","journal-title":"Cancer Diagn Progn"},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2152-2650(25","article-title":"MM-1315: higher mortality among african americans with multiple myeloma: A CDC WONDER analysis of racial and regional disparities (1999\u20132020)","author":"Tayyab","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122075","article-title":"Predictive and prognostic factors associated with the incidence and mortality of hematologic Malignancies","volume":"134","author":"Deloughery","year":"2019","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e13595","article-title":"Impact of socioeconomic status on the incidence and mortality of multiple myeloma in the United States","volume":"38","author":"Omore","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6498","article-title":"Abstract 6498: Association of lifestyle related risk factors with multiple myeloma mortality rates in the United States","volume":"83","author":"Gaddam","year":"2023","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19570","article-title":"Impact of declining renal function on multiple myeloma (MM) mortality in the U.S. (1999-2023): A regression analysis using the CDC WONDER database","author":"Faisal","year":"2025","journal-title":". J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25","article-title":"MM-1180: persistent disparities in multiple myeloma and renal disease mortality across US demographics and regions (1999\u20132020): A CDC WONDER database analysis","volume":"25","author":"Ibrahim","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01712-9","article-title":"MM-596 underlying cause of death in patients with multiple myeloma: A 21-year mortality analysis","volume":"24","author":"Aijaz","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"14564","DOI":"10.1038\/s41598-024-65590-4","article-title":"Multiple myeloma incidence and mortality trends in the United States, 1999\u20132020","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211653","article-title":"Multiple myeloma mortality trends and racial disparities in the United States and texas: A 20-year study (1999-2020): CDC wonder database","volume":"144","author":"Naz","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-021-01454-w","article-title":"Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race\/ethnicity","volume":"32","author":"Casta\u00f1eda-Avila","year":"2021","journal-title":"Cancer Causes Control"},{"key":"B24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.2016.68.3805","article-title":"Association between treatment facility volume and mortality of patients with multiple myeloma","volume":"35","author":"Go","year":"2017","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283304","article-title":"Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis","author":"Wei","year":"2023","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130859","article-title":"Racial and socioeconomic disparities in the utilization of autologous stem cell transplant for treatment of multiple myeloma in the era of novel agents","volume":"134","author":"Vardell","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jnma.2025.08.096","article-title":"Racial disparities in myeloma care: examining access to bispecific therapies, treatment patterns and outcomes among minority patients","volume":"117","author":"Tyes","year":"2025","journal-title":"J Natl Med Assoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01711-7","article-title":"MM-593 sociodemographic trends in multiple myeloma-related mortality from 1999 to 2020 and effect of the COVID-19 pandemic","volume":"24","author":"Aijaz","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280857","article-title":"Proteasome inhibition: the dawn of novel therapies in multiple myeloma","volume":"107","author":"Engelhardt","year":"2022","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.023","article-title":"Trends in early mortality from multiple myeloma: A population-based analysis","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34760","article-title":"A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma","volume":"129","author":"Grant","year":"2023","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02618-7","article-title":"MM-581: tracking mortality in multiple myeloma-associated acute kidney injury: U.S. Trends (1999\u20132023) and ARIMA-based projections through 2050","volume":"25","author":"Zubair","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011457","article-title":"Deciphering racial disparities in multiple myeloma outcomes","volume":"8","author":"Bertrand","year":"2024","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545459","article-title":"Impact of social vulnerability index on multiple myeloma mortality","author":"Tan","year":"2025","journal-title":"Oncology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)01936-6","article-title":"CML-520: comparison of trends in hospice use among patientsWith myeloid and lymphoid Malignancies based on sex and race (2003\u20132020): A CDC WONDER database analysis","volume":"25","author":"Ahmad","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19571","article-title":"Mortality trends in patients with multiple myeloma and renal failure in the United States (1999\u20132020): A CDC WONDER database analysis","volume":"43","author":"Nasir","year":"2025","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-25-0311","article-title":"An ecologic analysis of the association of regional cancer center presence with cancer mortality for the continuous United States","volume":"34","author":"Duncan","year":"2025","journal-title":"Cancer Epidemiology Biomarkers Prev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.023","article-title":"Assessment of the hematopoietic cell transplantation comorbidity index in older patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation","author":"Pollack","year":"2013","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3980.3980","article-title":"Treatment patterns and outcomes in elderly patients with multiple myeloma","volume":"118","author":"Bang","year":"2011","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24389","article-title":"Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients","volume":"91","author":"R\u00edos-Tamayo","year":"2016","journal-title":"Am J Hematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)33648-6","article-title":"Comorbidity index in elderly myeloma patients: does it affect clinical outcomes","author":"Kim","year":"2012","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.10033","article-title":"Patient-reported comorbidity and survival in older adults with cancer","volume":"35","author":"Williams","year":"2017","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124971","article-title":"Frailty in older adults with multiple myeloma: A study of United States veterans","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.12046","article-title":"Impact of geriatric assessment (GA) based frailty index (CARE-Frailty Index) on mortality and treatment-related toxicity among older adults with gastrointestinal (GI) Malignancies","volume":"39","author":"Giri","year":"2021","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/10428194.2024.2419375","article-title":"Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice","volume":"66","author":"Pianko","year":"2024","journal-title":"Leukemia Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201310","article-title":"Stratifying \u2018frail\u2019 Patients defined by the simplified frailty scale in multiple myeloma: correlation with clinical outcomes","volume":"144","author":"Kato","year":"2024","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02565-0","article-title":"MM-129: trends in septicemia-related mortality among adults with multiple myeloma: A 22-year nationwide analysis (1999\u20132020)","volume":"25","author":"Khan","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7553","article-title":"Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19","volume":"42","author":"Zolotov","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1735565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:23Z","timestamp":1765521263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1735565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":48,"alternative-id":["10.3389\/fonc.2025.1735565"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1735565","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1735565"}}